[To the Editor]{.smallcaps}---Convalescent plasma has been regarded as a promising treatment option for coronavirus disease 2019 (COVID-19) \[[@CIT0001]\]. However, its effect on survival rate in critically ill patients is controversial. To date, several studies have reported beneficial effects of convalescent plasma therapy on the survival rate in patients with severe COVID-19 or critically ill with COVID-19 \[[@CIT0004]\]; on the contrary, 5 of 6 critically ill patients died in our group's previous study \[[@CIT0010]\].

We thank Dr Malkovsky for his concern regarding our study of convalescent plasma therapy for COVID-19. However, we do not agree that the high mortality rates may be associated with unknown levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--neutralizing antibodies. We do agree that neutralizing antibody titers should be tested in convalescent plasma before treatment in future clinical studies or practice, if possible. We also agree that therapeutic plasma exchange with convalescent plasma may be a potential option for the treatment of critically ill patients with COVID-19.

Although we did not have the ability to test the amounts of antibody at the time of convalescent plasma therapy in mid- and late February 2020, we were certain that there were antibodies from donors who had recovered from COVID-19, because all donors have been tested by the Henan Provincial Red Cross Blood Center, the leading official Blood Center in Henan Province, China. Most importantly, all 6 patients had SARS-CoV-2 clearance within 3 days after the first convalescent plasma infusion, which strongly suggests the presence of neutralizing antibodies in the convalescent plasma.

However, it is worthwhile to consider why there was the huge disparity in survival rates between the 2 studies \[[@CIT0006], [@CIT0010]\] that Malkovsky mentions. We present the clinical characteristics of our 11 patients in [Table 1](#T1){ref-type="table"}. The interval between symptom onset and plasma transfusion was 21.5 (range, 13.8--23.3) days in survivors and 30 (25--31.5) days in nonsurvivors (*P* = .009). Nearly 10 days of delay in convalescent plasma therapy means more than the time itself alone, and as time goes by, the cytokine storm may be more severe. Therefore, relatively late initiation of the convalescent plasma therapy at the end stage of COVID-19 may be the main reason for the high mortality rate in our study.

###### 

Clinical Characteristics of 11 Patients Treated with Convalescent Plasma in 2 Studies

  Study and Patient No.       Sex      Age, y   Time From Symptom Onset to Plasma Transfusion, d   Respiratory Failure   Convalescent Plasma Treatments, No.   Convalescent Plasma Dosage, mL   Survival
  --------------------------- -------- -------- -------------------------------------------------- --------------------- ------------------------------------- -------------------------------- ----------
  Shen et al \[[@CIT0006]\]                                                                                                                                                                     
  1                           Male     73       24                                                 Yes                   1                                     400                              Yes
  2                           Male     60       14                                                 Yes                   1                                     400                              Yes
  3                           Female   50       22                                                 Yes                   1                                     400                              Yes
  4                           Female   36       21                                                 Yes                   1                                     400                              Yes
  5                           Male     60       23                                                 Yes                   1                                     400                              Yes
  1                           Male     32       13                                                 Yes                   1                                     200                              Yes
  Zeng et al \[[@CIT0010]\]                                                                                                                                                                     
  2                           Female   30       26                                                 Yes                   2                                     600                              No
  3                           Male     76       33                                                 Yes                   2                                     400                              No
  4                           Male     61       30                                                 Yes                   2                                     600                              No
  5                           Male     62       23                                                 Yes                   1                                     200                              No
  6                           Male     83       30                                                 Yes                   1                                     200                              No

Currently, many patients are receiving a one-time dose of convalescent plasma, while some receive 2 doses and larger volumes of convalescent plasma. In our view, convalescent plasma given earlier in the course of the disease may be more beneficial, and more important than either the dosing schedule or the antibody titers. The most effective regimen with respect to timing, titer, and dosing needs further clarification.
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